Nitric Oxide Nasal Spray Reduces Covid-19 Viral Load By 95% Within 24 Hours: Study
A well known antimicrobial, Nitric Oxide, has been found to rapidly reduce SARS-CoV-2 viral load, knocking it down by 95% within 24 hours, and 99% within 72 hours, according to a recent study by researchers funded by England's NHS foundation trust and SaNOtize Research & Development Corporation - a Canadian biotech company currently conducting Phase II trials of a nitric oxide nasal spray.
A group of 80 adults (18-70 years) with confirmed (Alpha strain) Covid-19 infections were divided into two groups, with half receiving nitric oxide nasal spray (NONS) that were self-administered 5-6 times daily for 9 days.
The goal of the nasal spray is to kill the virus present in the upper airways - preventing it from incubating and making its way to the lungs.
The study found that mean viral load was significantly lower in the NONS group by a factor of 16.2, in what the study's authors described as an "accelerated decrease," while nearly half of those who completed a post-study questionnaire reported feeling better vs. 8% of the placebo group.
Mean SARS-CoV-2 RNA concentration was lower on NONS by a factor of 16.2 at days 2 and 4. A rapid reduction (95%) in the SARS-CoV-2 viral load was observed within 24 hours, with a 99% reduction observed within 72 hours with NONS treatments. -Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.
What's more, there were no serious adverse reactions from the nasal spray.
"Treatment with NONS in this trial was found to be effective and safe in reducing the viral load in patients with mild, symptomatic COVID-19 infection," reads the study. "Patients in the NONS treatment arm demonstrated viral loads, as determined from PCR testing of nose and throat swab sampling, that were lower at days 2 and 4 by a factor of 16.2 than those on placebo, and symptom resolution was also found to be faster on NONS treatment than on placebo in this study."
Lower SARS-CoV-2 RNA loads in patients with NONS may be beneficial in the prevention of SARS-CoV-2 transmission. It has been described that higher viral loads in patients with SARS-CoV-2 earlier than SARS-CoV may have contributed to greater difficulties in reducing the onward transmission. Furthermore, it has been observed that the risk of symptomatic COVID-19 was associated with the SARS-CoV-2 RNA levels of contacts and incubation time was shortened in a dose-dependent manner.
Accelerated SARS-CoV-2 clearance with NONS may reduce symptom duration, decrease infectivity period, reduce hospital admissions, and lower disease severity. Consequently, this study could be used as supporting evidence for emergency use of NONS for patients with mild COVID-19 infection.
According to SaNOtize, researchers from Utah State University were able to kill 99.9% of SARS-CoV-2 in a petri dish within two minutes.
The company, whose board includes Prof. Ferid Murad of Stanford University - who won the Nobel Prize in 1998 for discovering the properties of nitric oxide, signed an agreement with Indian biotech Glenmark earlier this month to manufacture, market and distribute NONS throughout Asia, including Singapore, Malaysia Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.
According to SaNOtize Chief Science Officer, Dr. Chris Miller, the nasal spray is a 'post-exposure' prevention akin to hand sanitizer.
"If you are outside, around people, and could be infected, you could use the spray and reduce the number of viruses in the nose, before it is becoming a full-blown infection. We have shown that even when people have a very high load of virus, the spray can significantly reduce the viral load," Miller said in May.
to widen the scope of financial, economic and political information available to the professional investing public.
to skeptically examine and, where necessary, attack the flaccid institution that financial journalism has become.
to liberate oppressed knowledge.
to provide analysis uninhibited by political constraint.
to facilitate information's unending quest for freedom.
our method: pseudonymous speech...
Anonymity is a shield from the tyranny of the majority. it thus exemplifies the purpose behind the bill of rights, and of the first amendment in particular: to protect unpopular individuals from retaliation-- and their ideas from suppression-- at the hand of an intolerant society.
The right to remain anonymous may be abused when it shields fraudulent conduct. but political speech by its nature will sometimes have unpalatable consequences, and, in general, our society accords greater weight to the value of free speech than to the dangers of its misuse.
Though often maligned (typically by those frustrated by an inability to engage in ad hominem attacks) anonymous speech has a long and storied history in the united states. used by the likes of mark twain (aka samuel langhorne clemens) to criticize common ignorance, and perhaps most famously by alexander hamilton, james madison and john jay (aka publius) to write the federalist papers, we think ourselves in good company in using one or another nom de plume. particularly in light of an emerging trend against vocalizing public dissent in the united states, we believe in the critical importance of anonymity and its role in dissident speech. like the economist magazine, we also believe that keeping authorship anonymous moves the focus of discussion to the content of speech and away from the speaker- as it should be. we believe not only that you should be comfortable with anonymous speech in such an environment, but that you should be suspicious of any speech that isn't.